With medical expertise persevering with to evolve and supply the newest options and therapy to sufferers, Samsung Electronics Switzerland has been aiding the development by growing its merchandise.
Samsung collaborated with Bottneuro AG, a Swiss MedTech startup devoted to bettering the analysis and therapy of Alzheimer’s illness and to deliver an progressive and enhanced diagnostic and therapy answer to sufferers. Bottneuro AG has chosen Samsung Galaxy Tab S8+ 5G Enterprise Version {hardware} to retailer and document remedy knowledge within the Bottneuro Answer.
Highly effective Remedy By means of Progressive Applied sciences
Bottneuro AG’s expertise identifies areas of the mind affected by the illness via 3D magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging knowledge. As soon as recognized, these areas will be focused and electronically stimulated with Miamind® neurostimulator expertise. The Galaxy Tab S8+ 5G Enterprise Version simplify dealing with the Bottneuro answer through a graphical interface.
Sufferers that suffer from dementia usually expertise diminished cognitive perform within the early levels of the illness, making the necessity for locating a tool that’s straightforward to function and perceive crucial for Bottneuro AG. With its intuitive interface and usefulness, the Galaxy Tab S8+ 5G Enterprise Version offered the optimum {hardware} for the Bottneuro answer.
“We have been searching for a easy and dependable answer for our utility. We discovered it with the Galaxy Tab S8+ 5G Enterprise Version and Samsung is giving us nice assist within the growth,” stated Julius Klaas, CTO of Bottneuro AG.
Seamless Options in a Single Galaxy Pill
The Galaxy Tab S8+ 5G Enterprise Version presents a plethora of options and capabilities. It comes with a high-resolution Tremendous AMOLED show offering good readability for each sufferers and healthcare suppliers and presents dependable long-lasting battery life.
The Miamind® neurostimulator can also be straight powered by the Galaxy Tab S8+ 5G Enterprise Version, and as soon as therapy is full, the Galaxy Tab S8+ robotically transmits diagnostic and therapy data contained inside the Bottneuro answer to Bottneuro AG through 5G knowledge connectivity, permitting sufferers to remain within the consolation of their dwelling. Moreover, the Galaxy Tab S8+ 5G Enterprise Version will be individually configured via Samsung Knox, retaining delicate knowledge and medical data non-public and guarded.
Partnerships for the Future
Groundbreaking improvements similar to these wouldn’t be attainable with out partnerships, and Samsung is proud to have been supporting and dealing with Bottneuro AG since its founding in 2021.
“We’re happy to supply Bottneuro AG a dependable, protected and easy answer with Samsung Knox and to assist their novel remedy strategy,” added Daniele Casella, Head of MX B2B Cell at Samsung Switzerland.
The effectiveness of Bottneuro AG’s new therapeutic therapy shall be examined in a number of medical research this yr. Whereas the therapy just isn’t commercially accessible but, Bottneuro AG and Samsung stay optimistic about progress that may be made to deal with Alzheimer’s illness.
For extra data on Bottneuro AG and Samsung’s partnership, go to Samsung Newsroom Switzerland, www.bottneuro.com or www.miamind.com.
